linjc16/ctgov huggingface dataset:
Evaluation of Wound Biofilm in Acute and Chronic Wounds

Study Overview
=================
Brief Summary
-----------------
Patients who present to a wound care center for management of their wounds will be evaluated clinically to establish if their wounds are chronic or acute. These patients will undergo standard of care management of their wounds. If debridement is indicated for the patient, the patient will be asked to participate in a study. Once the standard of care debridement is complete, the material debrided from the wound, instead of being discarded into a biohazard bag, will be prepared for shipment. The samples will then be shipped to the Center for Biofilm Engineering where microscopic evaluation will be conducted on the material. Conclusion will be made from that analysis.

Detailed Description
-----------------
A planktonic concept of the bacteria present on the surface of a chronic wound is no longer viable. Microscopic studies show that biofilm is present on chronic wounds yet does not seem to be prominent on the surface of acute wounds. Biofilm is able to neutralize our host defenses and commandeer host systems, and possesses an impressive array of defenses and virulence factors. Clinically we see a significant difference in the healing behavior between chronic and acute wounds. Also, suppression of biofilm using multiple simultaneous strategies including debridement, anti-biofilm agents, specific biocides, antibiotics and advanced technologies improves wound healing. This suggests biofilm plays an important role in delayed wound healing.

Official Title
-----------------
Evaluation of Wound Biofilm in Acute and Chronic Wounds

Conditions
-----------------
Wounds

Intervention / Treatment
-----------------
* Other: no treatment


Participation Criteria
=================

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| no treatment<br> | Other: no treatment<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| It is important for all wound care providers to firmly grasp the wound biofilm concept, its importance in delayed wound healing, and how it differs from a planktonic bacterial concept. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute and Chronic Wounds
A Pilot Study to Obtain Preliminary Information Regarding the Efficacy and Safety of the Combination of Immune Globulin and Ganciclovir as Compared to Ganciclovir Alone in the Treatment of Sight-Threatening CMV Retinitis in Patients With AIDS

Study Overview
=================
Brief Summary
-----------------
To evaluate whether immune globulin and ganciclovir (DHPG) results in faster initial response as compared to DHPG alone. To evaluate whether immune globulin and DHPG gives longer duration of remission than DHPG alone (i.e. 16 weeks). To evaluate the toxicities of the combination of DHPG and immune globulin as compared to those of DHPG alone. To evaluate if there is a difference between the two groups in regard to survival, immune functions, and CMV viremia and viruria.

Official Title
-----------------
A Pilot Study to Obtain Preliminary Information Regarding the Efficacy and Safety of the Combination of Immune Globulin and Ganciclovir as Compared to Ganciclovir Alone in the Treatment of Sight-Threatening CMV Retinitis in Patients With AIDS

Conditions
-----------------
Cytomegalovirus Retinitis, HIV Infections

Intervention / Treatment
-----------------
* Drug: Globulin, Immune
* Drug: Ganciclovir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients must have the following: First episode of sight-threatening CMV retinitis. At least one pending culture for CMV from the blood or urine prior to entry. Life expectancy > 6 months. Karnofsky performance = or > 60. Ability to understand the nature of the study, to comply with study requirements, and to sign informed consent. Exclusion Criteria Co-existing Condition: Patients with the following conditions are excluded: Known selective IGA deficiency or antibodies against IgA. History of previous episodes of sight-threatening CMV retinitis. Patients with the following are excluded: Previous episode of sight-threatening CMV retinitis. Concomitant treatment with other investigational agents except ddI or ddC. Life expectancy < 6 months. Continued alcohol or drug abuse. Known selective IgA deficiency and known to have antibodies against IgA. Karnofsky performance <60. Other investigational agents except ddI or ddC. ddI ddC

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Globulin, Immune|nan|
|Drug: Ganciclovir|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Retinitis, Gamma-Globulins, Ganciclovir, Drug Therapy, Combination, Cytomegalovirus Infections, Acquired Immunodeficiency Syndrome, Immunization, Passive
Pharmacogenetic Testing in Children With Persistent Gastroesophageal Reflux Disease

Study Overview
=================
Brief Summary
-----------------
This study will use a 22 gene pharmacogenomics panel on 30 children with persistent Gastroesophageal Reflux Disease (GERD) who have not responded to therapy.

Detailed Description
-----------------
This study will assess the clinical utility of pharmacogenomics testing in the clinical management of children with refractory GERD, despite adequate therapy and the role of pharmacogenomics in selecting the right acid suppressive therapy based on each patient's symptoms and pharmacogenomics results.

Official Title
-----------------
The Utility of Pharmacogenetic Testing in Managing Children With Persistent Gastroesophageal Reflux Disease Despite Therapy

Conditions
-----------------
Gastroesophageal Reflux

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: persistent gastrointestinal symptoms (GI) suggestive of gastro esophageal reflux disease (GERD) despite adequate therapy persistent evidence of abnormal reflux indices' and acid exposure on esophageal multichannel pH impedance study despite adequate therapy persistent endoscopic evidence of reflux esophageal disease despite adequate therapy Exclusion Criteria: children with eosinophilic esophagitis diagnosis children with any esophageal surgical intervention like fundoplication, tracheoespahgeal fistula repair or esophageal atresia repair children with other diseases that can affect the esophagus, like Crohn's disease or food protein-induced enterocolitis syndrome (F-PIES) Children who do not have research authorization in their chart

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of subjects who change medication due to pharmacogenomic results |  | 12 weeks | 
| Number of subjects who have a repeat scope |  | 12 weeks |
Study On the Role of Mitochondrial Dysfunction in the Pathogenesis of Metformin-associated Lactic Acidosis

Study Overview
=================
Brief Summary
-----------------
Metformin is the first line drug of choice for the treatment of type II diabetes. Lactic acidosis can develop as a side effect, especially when renal failure leads to drug accumulation. Lactic acidosis is usually attributed to an abnormal inhibition of hepatic lactate clearance. Growing evidence suggest that metformin can dose-dependently inhibit hepatocyte mitochondrial function. Whether a similar effect occurs in extra-hepatic human tissues remains unknown. The investigators hypothesize that mitochondrial dysfunction occurs during metformin intoxication even in tissues other than the liver, thus contributing to the development of lactic acidosis. The aim of this study is to investigate mitochondrial integrity in circulating platelets of patients with lactic acidosis due to metformin intoxication.

Official Title
-----------------
On the Role of Mitochondrial Dysfunction in the Pathogenesis of Metformin-associated Lactic Acidosis

Conditions
-----------------
Lactic Acidosis, Metformin

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Lactic acidosis (pH < 7.35 or base deficit > 5 mmol/L and lactate > 5 mmol/L) Metformin intoxication (serum drug level > 4 mcg/mL) Absence of evidence of any other condition that could primarily explain the lactic acidosis Exclusion Criteria: Less than 18 years of age Hemoglobin < 8 g/dL (10 g/dL if ischemic cardiac disease)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Platelet mitochondrial respiratory chain enzyme activity |  | Within 48 hours from admission to ICU |
Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function

Study Overview
=================
Brief Summary
-----------------
The is study will examine whether variation in clinical bleeding frequency and severity among boys with severe Hemophilia A (Factor VIII deficiency) is associated with variations in laboratory measurements of platelet activity.

Official Title
-----------------
Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function

Conditions
-----------------
Hemophilia A

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: documented circulating FVIII level of ≤1% age 3 - 20 years may be on primary or secondary prophylaxis granting of informed consent Exclusion Criteria: measurable inhibitor level at the time of enrollment ingestion of aspirin/supplement known to influence platelet function within 14 days of blood sampling, or ibuprofen within 3 days

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 20 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hemophilia A<br>Boys with Factor VIII coagulant activity less than or equal to 1%. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Procoagulant platelet-derived microparticle formation |  | At time of enrollment | 
| Platelet aggregation | Whole blood platelet aggregation responses | At time of enrollment |
Impact and Burden of Rugby Injuries in Argentina. A Complete Season Retrospective Multicentric Study.

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to describe the prevalence, incidence and injury load suffered in male amateur rugby players from Argentina during a competitive season in 2019.

Detailed Description
-----------------
Introduction: Currently, Rugby is a sport that is giving priority to the well-being of the player. Players are subjected to high training and match loads exposing them to constant stress that can lead to overload injuries in addition to frequent contact injuries. Despite knowing what the situation is like at the international and national level, the Unión Argentina de Rugby lacks conclusive epidemiological data. Our main purpose was to describe the prevalence, incidence and injury load suffered in male amateur rugby players from Argentina during a competitive season in 2019. Design: Observational, descriptive, retrospective and multicenter study. Participants: 250 male amateur rugby players belonging to three clubs from three rugby unions (Buenos Aires, Córdoba and Rosario) of Argentina. Methods: Registration methods were applied according to the consensus of the World Rugby by a single observer per center. Injuries occurred in players from top rosters of 3 amateur rugby clubs (data collection centers) as well as the number of matches and hours of training were recorded. Medical diagnoses were classified under the rules of the OSIICS classification system. The incidence (injuries / 1000 hours-game-player), prevalences (point and period), the severity (days of absence) and the injury load will be calculated as well as the location, type, nature. This study followed the guidelines of the STROBE-SIIS Initiative Declaration.

Official Title
-----------------
Showing the Truth: Impact and Burden of Rugby Injuries in Argentina. A Complete Season Retrospective Multicentric Study.

Conditions
-----------------
Injuries

Intervention / Treatment
-----------------
* Other: No Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: >18 years Participation in more than 80% during training and matches of the competitive season. First, intermediate, Pre-intermediate A and Pre-intermediate B categories of the University teams of Córdoba, Old Resian and Los Matreros, belonging to UAR member unions. Exclusion Criteria: - Lost patient data
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No Intervention|Not Apply|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Injury Incidence | injuries/1000 hours-player | 9 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
epidemiology, Incidence, Injury severity, Football
Costs of Complications in Inguinal Hernia Repair

Study Overview
=================
Brief Summary
-----------------
Laparoscopic inguinal hernia repair is becoming increasingly popular mainly because of short-term advantages compared to open hernioplasties with mesh. In the prevailing economic climate, the total costs of treatment is a subject of intense research. This study is designed to evaluate the results of open and laparoscopic inguinal hernia repairs, with a special emphasis in costs of treatment, complications and convalescence.

Conditions
-----------------
Inguinal Hernia, Complication

Intervention / Treatment
-----------------
* Procedure: inguinal hernia surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients treated surgically for inguinal hernia between 2002-2011 Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| LAP repair<br>patients receiving laparoscopic inguinal hernia repair | Procedure: inguinal hernia surgery<br> <br> |
| open repair<br>patients receiving open flat mesh repair of inguinal hernia | Procedure: inguinal hernia surgery<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cost of complication | any complication associated with hernia surgery within 3 years, and its total costs | 3 years | 
| cost of primary treatment | the in-hospital costs of inguinal hernia repair surgery and the costs of convalescence following surgery | 2 months |
Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to see if it is safe and effective to give combinations of three or four anti-HIV drugs to HIV-infected patients. The drugs used in this study are delavirdine (DLV), nelfinavir (NLF), didanosine (ddI), and stavudine (d4T).

Detailed Description
-----------------
This is a multicenter, open-label study. Patients are stratified by HIV-1 RNA levels (20,000 to 200,000 copies/ml and greater than 200,000 copies/ml). Patients are equally randomized to one of four groups and receive antiretroviral therapy for 24 weeks. Group 1 receives delavirdine (DLV) plus nelfinavir (NFV) plus stavudine (d4T). Group 2 receives DLV plus NFV plus didanosine (ddI). Group 3 receives NFV plus d4T plus ddI. Group 4 receives DLV plus NFV plus d4T plus ddI. Patients are evaluated for drug safety and viral burden. Patients may opt to continue on the study for 24 additional weeks, at the discretion of the investigator.

Official Title
-----------------
An Open-Label Randomized Study of Delavirdine Mesylate (DLV, Rescriptor) Plus Nelfinavir (NFV), Didanosine (ddI), and Stavudine (d4T) in Triple and Quadruple Treatment Regimens in HIV-1 Infected Individuals

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: Nelfinavir mesylate
* Drug: Delavirdine mesylate
* Drug: Stavudine
* Drug: Didanosine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria You may be eligible for this study if you: Are at least 18 years old. Are HIV-positive. Have a CD4 count of at least 50 cells/mm3. Have a viral load of at least 20,000 copies/ml. Exclusion Criteria You will not be eligible for this study if you: Have taken d4T. Have taken protease inhibitors, including NFV. Have taken nonnucleoside reverse transcriptase inhibitors. Have taken ddI for 1 month or more.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Nelfinavir mesylate|nan|
|Drug: Delavirdine mesylate|nan|
|Drug: Stavudine|nan|
|Drug: Didanosine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV-1, Didanosine, Stavudine, HIV Protease Inhibitors, RNA, Viral, Delavirdine, Reverse Transcriptase Inhibitors, Viral Load, Nelfinavir
Trial of Cyclosporine in the Acute Phase of Leber Hereditary Optic Neuropathy

Study Overview
=================
Brief Summary
-----------------
The Leber Hereditary Optic Neuropathy is a genetic disorder caused by maternal transmission of mitochondrial DesoxiroboNucleid Acid mutations. It is manifested by a rapidly progressive blindness, profound, due to atrophic optic nerve. The visual loss is primarily unilateral bilateralisation taking place in the vast majority of cases in weeks or months. The neuro-cardio-protective properties of cyclosporine (and its analogs specifically targeting the anti-apoptotic mechanisms) are particularly promising. The investigators hypothesis is that cyclosporine may limit apoptosis during the acute phase of the disease process and would limit the loss of visual acuity and improve the visual prognosis of these patients.

Conditions
-----------------
Leber Hereditary Optic Neuropathy

Intervention / Treatment
-----------------
* Drug: cyclosporine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient with the mutation confirmed by molecular analysis patient with a recent loss of monocular vision (≤ 6 months) voluntarily Patient Consent Exclusion Criteria: patient who have not given their written and informed consent signed against indication of cyclosporine no drug compliance to previous inclusion no national health insurance affiliation pregnant women or lactating women who could become pregnant during the study period and with no contraception private patients of their liberty by judicial or administrative decision, or patients under supervision

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: cyclosporine<br> | Drug: cyclosporine<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement of visual acuity with Monoyer, Early Treatment Diabetic Retinopathy Study and Parinaud scales |  | at 9 months |
Pronostic Factors of Long Term Outcome in Patients With Clubfoot Treated by the Ponseti Method

Study Overview
=================
Brief Summary
-----------------
We aim at finding prognostic factors of long term (after growth) function outcome in patient with clubfoot treated by ponseti method, based on a very complete prospective recording of treatment variables and outcome

Official Title
-----------------
Pronostic Factors of Long Term Outcome in Patients With Clubfoot Treated by the Ponseti Method

Conditions
-----------------
Clubfoot

Intervention / Treatment
-----------------
* Other: ponseti


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Patients treated by ponseti method for clubfoot- Exclusion Criteria: - other malformation associated / congenital

Ages Eligible for Study
-----------------
Minimum Age: 3 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ponseti<br>Patients treated by ponseti method | Other: ponseti<br>* Standard of care, treatment by ponseti method<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Function at >16 years | Composite score (perfect or non-perfect function), perfect foot defined as a plantigrade, non painful, valgus barefoot with >10° dorsal flexion. Non-perfect otherwise. | at 18 years old or complete bone maturity |